Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Genome Editing Market Size Was Valued at USD 7.39 Billion in 2023, and is Projected to Reach USD 30.78 Billion by 2032, ...

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

Flashpoint Therapeutics, a clinical-stage therapeutics company pioneering structural nanomedicine, today announced significant expansion of its therapeutic pipeline through strategic acquisitions and ...

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, ...

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

The Cas nuclease market is on an upward trajectory, forecasted to grow from $2.75 billion in 2023 to $3.27 billion in 2024, at a CAGR of 18.9%. Key drivers include the rapid advancements in genome ...

University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...

Wood’s flagship tech and momentum stock fund is getting a big boost from Tesla and Coinbase. But it continues to underperform ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

Salim Syed’s rating is based on a combination of encouraging developments surrounding Crispr Therapeutics AG. Firstly, the pricing of Casgevy in Saudi Arabia appears to be around $2 million per ...